ImmunityBio (NASDAQ:IBRX) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of ImmunityBio (NASDAQ:IBRX) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $30.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Stock Performance

Shares of ImmunityBio stock opened at $2.76 on Monday. The business’s 50 day moving average price is $4.19 and its 200 day moving average price is $4.46. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -3.00 and a beta of 0.86. ImmunityBio has a one year low of $2.50 and a one year high of $10.53.

Institutional Investors Weigh In On ImmunityBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IBRX. Captrust Financial Advisors purchased a new position in shares of ImmunityBio during the 3rd quarter worth $41,000. Virtu Financial LLC purchased a new position in ImmunityBio during the third quarter worth about $51,000. Algert Global LLC purchased a new position in ImmunityBio during the second quarter worth about $86,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after acquiring an additional 4,545 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new position in shares of ImmunityBio in the 2nd quarter worth approximately $105,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.